The FDA on April 23 approved ADC Therapeutics’ Zynlonta for the treatment of diffuse large B-cell lymphoma (DLBCL) in adult patients who have received two previous therapies. Zynlonta is the first single-agent CD19-targeted antibody drug conjugate approved to treat the disease. Other novel therapies approved to treat DLBCL in recent years include Novartis’ Kymriah, which holds covered or better status for 29% of all insured lives under the pharmacy benefit, and Gilead Sciences’ Yescarta, which is covered or better for 30% of all lives.

SOURCE: MMIT Analytics, as of 4/26/21